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IVF failure is hypercoagulability, manifested by thrombo-
sis of maternal blood vessels of placental bed3,5. Hereditary 
thrombophilia is found in 1% of the general population, 
while the Factor V Leiden mutation, which is also the most 
common one found in about 5% of the Caucasian7. Other 
frequent mutations are ones in the gene for prothrombin 
G20210A, antithrombin, protein C and S defi ciency, muta-
tions in the methyltetrahydrofolate reductase (MTHFR) 
and plasminogen activator inhibitor (PAI-1) gene.
Consequently, screening and treatment of patients car-
riers of mutations is often used to improve obstetric out-
comes8. That is why many recommend screening for 
thrombophilia in women before engaging in IVF treat-
ment. Unfortunately, the effi cacy of this form of interven-
Introduction
Thrombophilia is a group of various hereditary and ac-
quired coagulation disorders often associated with an in-
creased risk of thrombosis. Various studies have shown 
that the success of in vitro fertilisation (IVF) in patients 
with thrombophilia is about 30%1. Several factors have 
been recognized to affect either success or failure rate of 
IVF/ET. Such factors include age, basal hormone levels, 
previously successful pregnancy, endometrial thickness, 
embryo grading and technique of ET2. Over the last de-
cade, inherited thrombophilia is oftenly referred as a pos-
sible cause of recurrent miscarriages, IVF/ET failure, 
embryo implantation and placentation. Further additional 
researches are needed in order to prove certain connec-
tions, because so far, they give confl icting results3–6. Many 
studies have suggested that the reason for the increased 
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A B S T R A C T
Thrombophilia is a group of inherited and acquired coagulation disorders often associated with an increased risk of 
thrombosis. Over the last decade, inherited thrombophilia is often referred as a possible cause of recurrent miscarriages 
and in vitro fertilisation (IVF) failure. However, many studies in this area still give confl icting results, so the goal of our 
study was to determine the effect of thrombophilia on pregnancy outcome and success of IVF. The study included 38 pa-
tients with proven gene mutation for thrombophilia and 53 patients without mutations. The studied parameters were age, 
duration of infertility, dose of gonadotropins, duration of stimulation, number of embryo transfer (ET), number of oocytes 
retrieved, the number of days to ET and the outcome in terms of delivery (full term or premature), ectopic pregnancy or 
abortion. There was no signifi cant difference between two groups in the number of procedures performed, the number of 
twin pregnancies, abortions, twin miscarriages, ectopic pregnancies, births and the etiology of infertility. A statistically 
signifi cant difference was found in the number of pregnancies (p=0.018) and in duration of infertility which was signifi -
cantly longer in the group with thrombophilia (p<0.001). The number of abortions in homozygous PAI-1 was signifi -
cantly more common (p=0.012). Procedures in natural cycle were signifi cantly more frequent in group with thrombophila 
(p=0.011), so we recommend in patients with proven mutation fi rst to start with procedures in the natural cycle, and only 
in case of failure to use the possibility of stimulating cycles. In conclusion, in patients on anticoagulant therapy a higher 
percentage of IVF failure has not been proven. Therefore, we strongly recommend the prophylactic use of low molecular 
weight heparin during pregnancy and screening for the most common mutations in our population, particularly in patients 
with a history of IVF failure and those with a long duration of infertility.
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TABLE 1
FREQUENCY OF CERTAIN MUTATIONS
N %
PAI-1
Homozygous 4 26.7%
Heterozygous 11.. 73.3%
MTHFR
Homozygous 2 33.3%
Heterozygous 4 66.7%
Double 
mutation
homozygous PAI-1+MTHFR 2 13.3%
heterozygous PAI-1+MTHFR 10.. 66.7%
homozygous PAI-1+heterozygous MTHFR 2 13.3%
heterozygous PAI-1+homozygous MTHFR 1   6.7%
Triple 
mutation
homozygous PAI-1+MTHFR+FII 1 50.0%
heterozygous PAI-1+MTHFR+FII 1 50.0%
PAI-1 – plasminogen activitor inhibitor, MTHFR – methyltetrahy-
drofolate reductase
TABLE 2
COMPARISON OF CATEGORICAL VARIABLES BETWEEN GROUPS WITH THROMBOPHILIA (A) AND WITHOUT THROMBOPHILIA (B): 
CHI-SQUARE TEST
Groups
Without thrombophilia (B) Thrombophilia (A)
p-value
N % N %
Procedures 
1 34 64.2% 16 42.1%
0.07
2 15 28.3% 11 28.9%
3   2   3.8%   6 15.8%
4   1   1.9%   4 10.5%
5   1   1.9%   1   2.6%
Pregnancy
0 29 54.7% 15 39.5%
0.0181 24 45.3% 18 47.4%
2   0     .0%   5 13.2%
Twin pregnancy 0 50 94.3% 36 94.7% 0.935
1   3   5.7%   2   5.3%
Abortion 0 48 90.6% 31 81.6% 0.211
1   5   9.4%   7 18.4%
Twin abortion 0 52 98.1% 38 100.0%.. 0.395
1   1   1.9%   0     .0%
Ectopic pregnancy 0 52 98.1% 35 92.1% 0.168
1   1   1.9%   3   7.9%
Birth 0 35 66.0% 20 52.6% 0.197
1 18 34.0% 18 47.4%
Time of birth Full term 17 94.4% 16 88.9% 0.546
Premature   1   5.6%   2 11.1%
Natural cycle
0 52 98.1% 29 76.3%
0.0111   1   1.9%   4 10.5%
2   0     .0%   4 10.5%
4   0     .0%   1   2.6%
Cause of infertility
Male 17 32.1% 16 42.1%
0.608Female 12 22.6%   8 21.1%
Mix 10 18.9%   8 21.1%
Unknown 14 26.4%   6 15.8%
tion is still unclear. Therefore the goal of our study was to 
determine the effect of thrombophilia on pregnancy out-
come and success of IVF.
Subjects and Methods
Subjects
The study was conducted between 2011 and 2013 at the 
Division of Human Reproduction and Gynecological En-
docrinology, Department of Gynecology and Obstetrics, 
Medical School University of Zagreb, Croatia. The study 
included 91 patients involved in the IVF procedure.
Indications for IVF were anovulation, unexplained in-
fertility and male or female factor of infertility. The inclu-
sion criterion was infertility in duration of at least a year. 
The patients were divided into 2 groups. The fi rst group 
(A) included 38 patients with mutations of the genes for 
thrombophilia (Table 1). The control group (B) comprised 
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53 patients without mutations. Exclusion criteries were 
previous thromboembolic incidents. All 38 patients from 
the fi rst group, in the case of a positive beta-human cho-
rionic gonadotropin (βHCG) 14 days after IVF procedure, 
were treated with 0.4 mL (1750 IU) of low molecular 
weight heparin until the end of pregnancy. A total of 156 
procedures were done, 77 in group A and 79 in group B. 
Out of 156 procedures, 17 of them were done in the natural 
cycle, 16 in group A and 1 in group B. In the remaining 
139 procedures all patients received standardized protocol 
ofcontrolled ovarian stimulation using the combination of 
gonadotropin-releasing hormone(GnRH) agonists and 
gondotropins. ET was preformed after each procedure. 
Patients age in both groups was approximately equal, with 
a range from 28 to 43 years (interquartile range 31.00 to 
39.25) in group A and 25 to 43 years (interquartile range 
30.00 to 37.00) in group B.
Studied parameters were age, duration of infertility, 
dose of gonadotropins, duration of stimulation, number of 
ET, number of retrieved oocytes, number of days until the 
ET and the outcomes, in terms of delivery (full term or 
premature), ectopic pregnancy or abortion.
Statistical analysis
The results were statistically analyzed and presented 
as percentages and medians (25–75 interquartile range). 
Chi-square test, the Mann-Whitney U test and Kruskal-
Wallis test were used. P-values less than or equal to 0.05 
are considered statistically signifi cant. Data analysis was 
performed in Statistica 10.0 (StatSoft, Inc., 2011, STATIS-
TICA data analysis software system version 10), and Mi-
crosoft Offi ce Excel 2003 program.
Results
The results of our study are presented in Table 2. There 
was no no signifi cant difference between two groups in the 
number of procedures performed, twin pregnancies, num-
ber of abortions, number of twin miscarriages, ectopic 
pregnancies, number of births or etiology of infertility. A 
statistically signifi cant difference was found in the num-
ber of pregnancies (p=0.018) and in the number of proce-
dures performed in the natural cycle (p=0.011). In group 
A, there were a total of 23 pregnancies, 18 patients with 
1 pregnancy (47.4%) and 5 patients with 2 pregnancies 
(13.2%), while in group B, there were a total of 24 preg-
nancies (45.3%).
The procedures in the natural cycle were signifi cantly 
more frequent in group A. In the total of 16 procedures, 4 
patients (10.5%) had one procedure in a natural cycle, 4 
patients (10.5%) had two procedures in natural cycle and 
only 1 patient (2.6%) had four procedures in the natural 
cycle. Statistically signifi cant differences in median val-
ues of quantitative variables between groups were found 
in the duration of infertility, which was signifi cantly lon-
ger in thegroup with thrombophilia (A) (interquartile 
range 4–8) compared to group B (interquartile range 2–5) 
(p<0.001).
TABLE 3
DIFFERENCES IN MEDIAN VALUES  OF QUANTITATIVE VARIABLES BETWEEN GROUPS MANN-WHITNEY U TEST
Groups N Min Max
Percentiles
p
25th 50th (Median) 75th
Age 
Without thrombophilia 53 25.00     43.00   30.00   34.00   37.00
  0.215
Thrombophilia 38 28.00     43.00   31.00   34.00   39.25
Duration 
of infertility
Without thrombophilia 49   1.00     13.00     2.00     4.00     5.00
<0.001
Thrombophilia 36   2.00     12.00     4.00     6.00     8.00
Number 
of oocytes
Without thrombophilia 53   1.00     32.00     3.00     6.00     9.00
  0.332
Thrombophilia 38   1.00     24.00     3.00     6.50   11.25
ET after 
X days
Without thrombophilia 53   3.00     17.00     3.00     5.00     6.00
  0.087
Thrombophilia 37   3.00     14.00     3.00     5.00     8.50
Dose 
of gonadotropins
Without thrombophilia 53 825.00.. 15675.00.. 1425.00.. 2025.00.. 3050.00..
  0.449
Thrombophilia 38 900.00.. 5175.00 1425.00.. 2512.50.. 3468.75..
Duration 
of stimulation
Without thrombophilia 53   8.00     58.00     9.50   11.00   23.00
  0.398
Thrombophilia 38   7.00     44.00   10.00   16.50   24.00
Number 
of ET
Without thrombophilia 53   1.00       9.00     2.00     2.00     3.00
  0.080
Thrombophilia 38   1.00       7.00     2.00     2.00     4.00
ET – embryo transfer
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TABLE 4
DIFFERENCES IN CATEGORICAL VARIABLES IN A GROUP OF THROMBOPHILIC PATIENTS ACCORDING
TO THE TYPE OF MUTATION
Mutation
 p-valuePAI1 MTHFR Double mutation Triple mutation
N % N % N % N %
Procedures 
1 6 40.0% 3 50.0% 4 57.1% 1 50.0%
0.771
2 4 26.7% 3 50.0% 2 28.6% 0     .0%
3 3 20.0% 0     .0% 0    .0% 1 50.0%
4 1   6.7% 0     .0% 1 14.3% 0     .0%
5 1   6.7% 0     .0% 0     .0% 0     .0%
Pregnancy 
0 7 46.7% 2 33.3% 3 42.9% 1 50.0%
0.3401 7 46.7% 2 33.3% 4 57.1% 0     .0%
2 1   6.7% 2 33.3% 0     .0% 1 50.0%
Twin 
pregnancy
0 150 100.0%0 5 83.3% 7 100.0%0 2 100.0%0
0.247
1 0     .0% 1 16.7% 0     .0% 0     .0%
Abortion 
0 130 86.7% 4 66.7% 6 85.7% 1 50.0%
0.503
1 2 13.3% 2 33.3% 1 14.3% 1 50.0%
Twin abortion 0 150 100.0%0 6 100.0%0 7 100.0%0 2 100.0%0 –
Ectopic 
pregnancy
0 140 93.3% 6 100.0%0 6 85.7% 1 50.0%
0.208
1 1   6.7% 0     .0% 1 14.3% 1 50.0%
Birth 
0 9 60.0% 2 33.3% 5 71.4% 2 100.0%0
0.322
1 6 40.0% 4 66.7% 2 28.6% 0     .0%
Time 
of birth
Full term 6 100.0%0 3 75.0% 2 100.0%0 0     .0%
0.336
Premature 0     .0% 1 25.0% 0     .0% 0     .0%
Natural 
cycle
0 110 73.3% 5 83.3% 6 85.7% 2 100.0%0
0.930
1 2 13.3% 1 16.7% 0     .0% 0     .0%
2 1   6.7% 0     .0% 1 14.3% 0     .0%
4 1   6.7% 0     .0% 0     .0% 0     .0%
Cause 
of infertility
Male 8 53.3% 2 33.3% 4 57.1% 0     .0%
0.150
Female 1   6.7% 2 33.3% 1 14.3% 2 100.0%0
Mix 4 26.7% 1 16.7% 0     .0% 0     .0%
Unknown 2 13.3% 1 16.7% 2 28.6% 0     .0%
PAI-1 – plasminogen activitor inhibitor, MTHFR – methyltetrahydrofolate reductase
Comparing the age of the patients, number of retrieved 
oocytes, dose of used gonadotropins, duration of stimula-
tion, number of days until ET and number of ET, we did 
not fi nd signifi cant differences (Table 3). Considering the 
type of mutation, in group A there were no signifi cant 
differences in categorical variables (Table 4).
Comparing the quantitative variables in group A, re-
garding the type of mutation, we did not fi nd signifi cant 
differences (Table 5). Due to the small number of MTHFR, 
certain double and triple mutation the analysis was con-
ducted only with PAI-1 mutation. The comparison of cat-
egorical variables between PAI-1 homozygous and hetero-
zygous, demonstrated a statistically signifi cant difference 
in the number of abortions. In PAI-1 homozygous abortion 
was signifi cantly more common (p=0.012) (Table 6). In the 
38 patients in group A, 15 of them were positive for the 
PAI-1 mutation, 4 homozygotes (26.7%) and 11 heterozy-
gotes (73.3%). In this group of patients 2 miscarriages 
(50%) were recorded, both PAI-1 homozygotes.
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TABLE 5
DIFFERENCES IN QUANTITATIVE VARIABLES IN A GROUP OF THROMBOPHILIC PATIENTS ACCORDING
TO THE TYPE OF MUTATION: THE KRUSKAL-WALLIS TEST
Mutation N Min Max
Percentiles
p
25th 50th (Median) 75th
Age 
PAI1 15 30 43 33.00 35.00 40.00
0.609
MTHFR   6 28 40 28.75 33.50 40.00
Double mutation   7 30 42 31.00 34.00 40.00
Triple mutation   2 33 34 24.75 33.50 25.75
Duration 
of infertility
PAI1 14   2 12   4.00   8.00 10.00
0.124
MTHFR   6   3   6   3.75   4.50   6.00
Double mutation   7   3 12   4.00   6.00   7.00
Triple mutation   2   3   4   2.25   3.50   3.25
Number 
of oocytes
PAI1 15   2 24   3.00   4.00 11.00
0.523
MTHFR   6   6 20   6.00   8.00 13.25
Double mutation   7   1 21   3.00   9.00 10.00
Triple mutation   2   6 17   4.50 11.50 13.00
ET after 
X days
PAI1 15   3 13   3.00   5.00   8.00
0.980
MTHFR   6   5   8   5.00   5.00   6.50
Double mutation   7   3 12   3.00   5.00   9.00
Triple mutation   2   3 13   2.25   8.00 10.00
Dose 
of gonadotropins
PAI1 15 1350.0 5175.0 1800.000 2250.000 3450.000
0.519
MTHFR   6 1150.0 3975.0 1356.250 2156.250 3468.750
Double mutation   7   900.0 3525.0   950.000 1575.000 2925.000
Triple mutation   2 1200.0 4125.0   900.000 2662.500 3094.000
Duration 
of stimulation
PAI1 15   9 34 10.00 16.00 20.00
0.645
MTHFR   6 10 44 10.00 19.50 35.00
Double mutation   7   7 24   9.00 11.00 19.00
Triple mutation   2   9 35   6.75 22.00 26.50
Number 
of ET
PAI1 15   1   6   2.00   2.00   4.00
0.856
MTHFR   6   1   4   1.75   3.00   4.00
Dvostruka mutacija   7   1   7   1.00   2.00   3.00
Trostruka mutacija   2   2   6   1.50   4.00   4.75
PAI-1 – plasminogen activitor inhibitor, MTHFR – methyltetrahydrofolate reductase, ET – embryo transfer
Comparing the quantitative variables in PAI-1 homo-
zygotes and heterozygotes we did not fi nd statistically sig-
nifi cant differences (Table 7). No thrombotic complications 
occured during IVF procedure or pregnancy in group A.
Discussion and Conclusion
This study showed that the presence of thrombophilia 
(PAI-1, MTHFR, double and triple mutations) does not 
increase the risk of IVF failure. In 38 patients from group 
A, 28 pregnancies were recorded, and in 53 patients from 
group B, 24 pregnancies, reaching statistical signifi cance 
of p=0.018. In patients with thrombophilia we recorded a 
slightly higher number of abortions and ectopic pregnan-
cies, however, they have not reached statistical signifi -
cance. In group A, there were 47.4% live births, and 34% 
in group B, but statistically signifi cant differences was not 
found. Our research has demonstrated signifi cantly longer 
duration of infertility among women with thrombophilia.
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TABLE 6
DIFFERENCES IN CATEGORICAL VARIABLES BETWEEN HOMOZYGOUS AND HETEROZYGOUS PAI-1
PAI-1
p-valueHomozygous Heterozygous
N % N %
Procedures 
1 2 50.0% 4 36.4%
0.311
2 0     .0% 4 36.4%
3 2 50.0% 1 9.1%
4 0     .0% 1 9.1%
5 0     .0% 1 9.1%
pregnancy
0 2 50.0% 5 45.5%
0.1911 1 25.0% 6 54.5%
2 1 25.0% 0 .0%
Twin pregnancy 0 4 100.0%0 110 100.0% –
Abortion 
0 2 50.0% 110 100.0%
0.012
1 2 50.0% 0 .0%
Twin abortion 0 4 100.0%0 110 100.0% –
Ectopic pregnancy
0 3 75.0% 110 100.0%
0.086
1 1 25.0% 0 .0%
Birth 
0 4 100.0%0 5 45.5%
0.057
1 0     .0% 6 54.5%
Time of birth
Full term 0     .0% 6 100.0%
–
Premature 0     .0% 0 .0%
Natural cycle
0 4 100.0%0 7 63.6%
0.576
1 0     .0% 2 18.2%
2 0     .0% 1 9.1%
4 0     .0% 1 9.1%
Cause of infertility
Male 2 50.0% 6 54.5%
0.321
Female 1 25.0% 0 .0%
Mix 1 25.0% 3 27.3%
Unknown 0     .0% 2 18.2%
PAI-1 – plasminogen activitor inhibitor
Despite numerous studies in this area, defi nitive an-
swers are not yet obtained. Qublanet al. have proved the 
existence of association of thrombophilia and implantation 
failure9. In their case-control studies 90 and 45 patients 
with recurrent IVF failures were included, and 90 (100), 
and 44 patients in the control group. Qublan et al. have 
proved the existence of more than three gene mutations 
among 10 investigated genes, in 74% of women with im-
plantation failure compared to 20% of patients in the con-
trol group (p=0.0004) 9. They concluded that hereditary 
thrombophilia is associated with implantation failure. 
The study results of Azem et al. (2004) showed that 42.9% 
of patients with 4 or more failed IVF cycles are positive 
for thrombophilia mutations, compared with 18.2% in the 
control group, and that everything points that inherited 
thrombophilia plays a role in the etiology of recurrent IVF 
failures, particularly in the subgroup with unexplained 
infertility5.
The results of our research, on the impact of thrombo-
philia on implantation, coincide with a number of stud-
ies10,11. Meta-analysis of Di Nisio et al. (2011) included a 
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TABLE 7
DIFFERNCES IN QUANTITATIVE VARIABLES IN THE GROUP OF THROMBOPHILIC PATIENTS DUE
TO THE PRESENCE OF PAI-1 MUTATION: MANN-WHITNEY U TEST
PAI-1 N Min Max
Percentiles
p
25th 50th (Median) 75th
Age 
Homozygous 4 31 41 32.00 37.00 40.50
0.851
Heterozygous 110 30 43 33.00 35.00 40.00
Duration 
of infertility
Homozygous 4   2 10   2.25   6.50 10.00
0.733
Heterozygous 100   4 12   5.50   8.00   9.25
Number 
of oocytes
Homozygous 4   3 11   3.75   7.50 10.50
0.571
Heterozygous 110   2 24   3.00   3.00 12.00
ET after 
X days
Homozygous 4   3 13   3.00   6.00 12.00
0.753
Heterozygous 110   3   9   3.00   5.00   6.00
Dose 
of gonadotropins
Homozygous 4 1350.0 5175.0 1518.750 2925.000 4837.500
0.661
Heterozygous 110 1350.0 3900.0 1800.000 2250.000 3300.000
Duration 
of stimulation
Homozygous 4 10 34 10.00 19.00 32.50
0.661
Heterozygous 110   9 29 10.00 16.00 19.00
Number 
of ET
Homozygous 4   2   6   2.00   3.50   5.75
0.343
Heterozygous 110   1   6   2.00   2.00   3.00
PAI-1 – plasminogen activitor inhibitor, ET – embryo transfer
total of 33 studies with 6092 patients and showed a high-
er failure rate in patients with Factor V Leiden mutation 
while other mutations, including MTHFR are proven as 
risk factors for adverse outcome10. Results of Roque et al. 
(2004) show that the presence of thrombophilia (Factor V 
Leiden and prothrombin) is not associated with pregnan-
cy loss of less than 10 weeks, on the other hand, a number 
of meta-analyzes confi rm the correlation especially in Fac-
tor V Leiden mutation with pregnancy loss12,13. But before 
the fi nal interpretation of our results we should consider 
the fact that all of our patients have been on the low mo-
lecular weight heparin, in case of a positive bHCG. Ques-
tion is whether low molecular weight heparin is the one 
that actually canceled the possible impact of thrombo-
philia on implantation and whether we should introduce 
heparin prophylaxis in all patients with thrombophilia?
There are studies that negate the need for screening 
for thrombophilia and which do not justify prophylactic 
administration of heparin, but there are studies that sug-
gest just the opposite, supporting screening and adminis-
tration of heparin. Research of Brenner et al. (2000) 
showed an increase in successfully completed pregnancies 
with the heparin treatment, from 20% in the untreated 
control group to 75% in the treated group4,14–16. There are 
studies that compare the effi cacy of taking the combina-
tion of low molecular weight heparin with aspirin or aspi-
rin intake only. Some studies provide very signifi cant 
preferences in the use of heparin prophylaxis while others 
refute these results, arguing that in asymptomatic pa-
tients with thrombophilia is possible to achieve good out-
comes without treatment17,18. Laskin et al. (2009) failed to 
prove a signifi cant advantage of the combination of hepa-
rin and aspirin compared to aspirin use alone19. While 
there is no evidence of adverse affects of aspirin or hepa-
rin, most doctors, if prophylaxis is needed, recommend 
administration of heparin17. To confi rm the prophylactic 
administration of heparin a number of randomized multi-
centric studies, with a large number of patients with dif-
ferent types of mutations, are required. Also, it is impor-
tant to note that it is very diffi cult to give the fi nal answer 
on the impact of thrombophilia on the outcome of IVF, 
because all researches generally consider only mother’s 
thrombophilia, while possible mutations in the embryo or 
fetus and father are not taken into account as important 
factor that may also have an impact on the outcome of IVF.
In our study,mutations in the gene for PAI-1 were con-
fi rmed in 15 patients (39.47%). 11 of 15 patients were het-
erozygotes and 4 homozygotes for the same mutation. 
Urokinase plasminogen activator and its receptor and 
PAI-1 are believed to control proteolysis and transforma-
tion of maternal tissue during the invasion of the tropho-
blast20,21. PAI-1 levels were associated with a polymor-
phism of genes. The most common are insertion/deletion 
of guanine, 675 bp upstream of the translation start site. 
It has been shown that homozygosity for the deletion gen-
otype 4G/4G is associated with higher concentrations of 
PAI-1 than in genotype 5G/5G, and consequently with re-
duced fi brinolytic activity22,23. Buchholz24 et al. (2003), 
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have shown that the rate of abortions, and signifi cantly 
higher relative risk of pregnancy loss are increased in this 
group of patients. Apart from mutations of PAI-1, Dossen-
bach-Glaninger et al. (2003) have shown that polymor-
phism of the coagulation factor XIII (FXIII) Val34Leu and 
4G/5G PAI-1 interfere with crosslinking of fi brin and fi -
brinolysis and can lead to early pregnancy loss25.
Our results showed signifi cantly more frequent number 
of abortions in homozygous PAI-1, actually, none of those 
pregnancies resulted in childbirth. So far in the literature 
results related with the role of PAI-1 mutations show con-
fl icting results. Before beginning our study all patients had 
their mutations confi rmed, but since the mutation of PAI-1 
resulted as the most common one in our study population, 
it would make sense to test all patients with long duration 
of infertility before conducting IVF or patients with recur-
rent IVF failures for the presence of these mutations. A 
signifi cantly smaller number of patients, to be precise 6 
(15.78%) were carriers of the MTHFR mutation, 2 homo-
zygotes and 4 heterozygotes.
In most studies the incidence of MTHFR mutation was 
between 18.8 to 22.2%4,5,9. MTHFR is an enzyme that 
catalyzes the reduction of 5–10 methyltetrahydrofolate 
and allows re-methylation of homocysteine to methionine. 
MTHFR mutations can lead to hyperhomocysteinemia.
Over the past 20 years, many studies cited MTHFR 
mutation as a risk factor for thrombosis and pregnancy 
loss, while others refuted that connection26–29. The exact 
mode of development of complications in pregnancy is not 
known, although the hypothesis is that hyperhomocyste-
inemia leads to endothelial damage, resulting in venous 
thromboembolism and placental insuffi ciency30. However, 
other studies refute this assumption. When comparing the 
concentration of homocysteine in patients with and with-
out a mutation of MTHFR, no signifi cant difference is 
found. Suggesting that fetal losses are not associated with 
homocysteine levels, and very likely there are other mech-
anisms31.
The analysis of our data did not detect a difference in 
categorical variables between individual mutations in the 
study. Due to the small number of patients, analysis of dif-
ferences between homozygous and heterozygous MTHFR 
was not preformed. Similarly homocysteine levels were not 
measured, since all patients were on treatment with folic 
acid. Possible reasons for different results obtained are 
relatively small number of patients in our study, and the 
inability to detect signifi cant differences that could be ap-
plied to most patients, in only 6 proven mutation, and for 
confi rmation it is necessary to do the research on a larger 
number of patients.
From a total of 38 patients from group A, 15 of them 
(39.47%) had a confi rmed double mutation. The most com-
mon form of double mutation (66.7%) was heterozygous 
combination of PAI-1 with heterozygous MTHFR, and the 
triple mutation was detected in only 2 patients. In our 
study, the existence of double or triple mutation has not 
been proven as a risk factor for pregnancy loss, however 
it should be noted that the number of patients included in 
study was relatively small. Coulam et al. (2006) showed 
that in the group of patients with recurrent implantation 
failure is signifi cantly greater number of mutated genes 
74% compared to the control group, 20%6. So far there 
were not any researches to determine whether there is 
greater risk of spontaneous abortion, pregnancy complica-
tions or IVF failure in patients with double or triple muta-
tions compared to patients with evidence of only one muta-
tion. The answer to that question still remains unclear.
Another statistically signifi cant difference was found 
in this study, and that is the conduction of IVF procedure 
in a natural cycle (P=0.011) in the group positive for 
thrombophilia. In the group positive for thrombophilia we 
found greater number of pregnancies, so it could suggest 
signifi cantly better IVF procedure outcome in the natural 
cycle in those patients. In patients with proven mutation, 
it is recommended to start fi rst with procedures in the 
natural cycle, and only in case of failure to use the possi-
bility of stimulation of cycles. However, for defi nitive proof 
of this results, further research is needed, especially using 
natural cycle in IVF procedures in a signifi cant number 
of patients. In conclusion, in patients on heparin therapy 
a higher percentage of failed IVF procedures and pregnan-
cies has not been proven. Therefore, we strongly recom-
mend the prophylactic use of low molecular weight heparin 
during pregnancy and screening for the most common 
mutations in our population, particularly in patients with 
a history of failed IVF and those with a long duration of 
infertility.
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UTJECAJ TROMBOFILIJE NA ISHOD TRUDNOĆE I IVF POSTUPAKA
S A Ž E T A K
Trombofi lija je skupina nasljednih i stečenih poremećaja koagulacije često povezanih s povećanom sklonošću trombozi. 
Tijekom posljednjeg desetljeća, nasljedna trombofi lija često se spominje kao mogući uzrok ponavljajućih pobačaja i 
neuspjelih in vitro fertilizacija (IVF). Međutim, mnoge studije u tom području još uvijek daju proturječne rezultate, tako 
da je cilj našeg istraživanja bio utvrditi utjecaj trombofi lije na ishod trudnoće i uspjeh IVF-a. U istraživanju je sudjelova-
lo 38 pacijentica s dokazanom mutacijom gena za trombofi liju i 53 pacijenatice bez mutacije. Istraživani parametri bili 
su dob, trajanje neplodnosti, doza gonadotropina, trajanje stimulacije, broj embrio transfera (ET), broj oocita, broj dana 
do ET i ishod svakog postupka u vidu poroda (terminski ili prijevremeni), ekstrauterine trudnoće ili pobačaja. Između 
skupine A i skupine B nije dokazana statistički značajna razlika u broju provedenih postupaka, blizanačkih trudnoća, 
broju pobačaja, broju blizanačkih pobačaja, ekstrauterinih trudnoća, broju poroda ili etiologiji neplodnosti. Statistički 
značajna razlika pronađena je u broju trudnoća (p=0,018) i u trajanju neplodnosti koja je značajno dulja u skupini s 
trombofi lijom (p<0.001). Broj pobačaja u homozigota PAI-1 je bio značajno češći (p=0,012). Postupci u prirodnom ciklusu 
su bili znatno češći u skupini s trombofi lijom (p=0,011), stoga preporučujemo kod bolesnika s dokazanom mutacijom prvo 
započeti s postupcima u prirodnom ciklusu, a tek u slučaju neuspjeha koristiti mogućnost stimulacije ciklusa. U zaključku, 
u pacijentica na terapiji heparinom nije dokazan veći postotak neuspjelih IVF postupaka i trudnoća. Stoga svakako 
preporučujemo profi laktičku primjenu niskomolekularnog heparina za vrijeme trudnoće te probir na najčešće mutacije 
u našoj populaciji, osobito u pacijentica s povijesti neuspjelih IVF postupaka i u onih s dugim trajanjem neplodnosti.
